Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

Bullboard Posts

Post by Francine01on Dec 19, 2017 4:13pm

129 Views

Post# 27190370

Absolute disaster

WTF. I don't know if Jan lost her job this week but she will have 15,000,000 shareholders that have just been wiped by the insane financing. the 0,9 warrant is probably never seen before.

Yesterday, wrote to her, if she could press release the Phase 3 beginning and annonce the CRO.

she f****** refused.

small compensation I reserved my stack of the new issuance, but we can only trade in 4-6 month in Canada !!

what a disaster ..

Bullboard Posts

How a truck transportation and logistics company leverages acquisitions and technology